A study shows that inhibiting EZH2 can reduce prostate cancer resistance to immune checkpoint therapy. It is suggested that the combination therapy of EZH2 inhibitor + immune checkpoint inhibitor can increase the effect of immunotherapy for prostate cancer and can be used as a promising treatment plan.
